1. Home
  2. FENG vs TPST Comparison

FENG vs TPST Comparison

Compare FENG & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

HOLD

Current Price

$1.53

Market Cap

18.0M

Sector

Industrials

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.10

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FENG
TPST
Founded
1998
2011
Country
China
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0M
15.6M
IPO Year
2011
2012

Fundamental Metrics

Financial Performance
Metric
FENG
TPST
Price
$1.53
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
2.0K
121.6K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$0.84
52 Week High
$3.65
$12.22

Technical Indicators

Market Signals
Indicator
FENG
TPST
Relative Strength Index (RSI) 53.50 58.83
Support Level $1.50 $1.02
Resistance Level $1.80 $1.09
Average True Range (ATR) 0.03 0.06
MACD 0.01 0.03
Stochastic Oscillator 87.50 85.46

Price Performance

Historical Comparison
FENG
TPST

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: